Three-year clinical outcome after primary scenting of totally occluded native coronary arteries: A randomized comparison of bare-metal stem implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study)

被引:43
作者
Rahel, Braim M. [1 ]
Laarman, Gerrit J. [2 ]
Kelder, Johannes C. [3 ]
ten Berg, Jurien M. [1 ]
Suttorp, Maarten J. [1 ]
机构
[1] St Antonius Hosp, Dept Intervent Cardiol, NL-3435 CM Nieuwegein, Netherlands
[2] Onze Lieve Vrouw Hosp, Dept Intervent Cardiol, Amsterdam, Netherlands
[3] St Antonius Hosp, Dept Res & Stat, NL-3435 CM Nieuwegein, Netherlands
关键词
LONG-TERM OUTCOMES; POOLED ANALYSIS; SUCCESSFUL RECANALIZATION; CONTROLLED-TRIAL; SLOW-RELEASE; DOUBLE-BLIND; WALL-MOTION; OFF-LABEL; C-SIRIUS; THROMBOSIS;
D O I
10.1016/j.ahj.2008.08.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The purpose of this study was to examine the 3-year clinical outcome in patients enrolled in the Primary Stenting of Totally Occluded Native Coronary Arteries II study. Methods Patients with totally occluded coronary arteries randomized to either sirolimus-eluting Cypher stents (SESs) (Cordis, a Johnson & Joshson Company, Miami Lakes, FL) (100 patients) or bare-metal BxVelocity stents (BMSs) (Cordis) (100 patients) were followed clinically for 3 years. Results Between 1 and 3 years, there were infrequent additional clinical events that were equally distributed between the SES and the BMS group. After: 3 years, target lesion revascularization was 7% in the SES group versus 27% in the BMS group (P < .001); and target vessel revascularization was seen in 11% in the SES group versus 30% in the BMS group (P = .002). Major adverse cardiac events were noted in 10% of the SES group versus 34% in the BMS group (P < .001). There were no statistically significant differences in death, myocardial infarction, and stent thrombosis according to the Academic Research Consortium criteria between the 2 groups. Conclusions Clinical outcome up to 3 years after implantation of SESs for total coronary occlusions continues to demonstrate a significant reduction in adverse clinical events compared with BMSs without the evidence for either disproportionate late restenosis or late stent thrombosis. (Am Heart J 2009;157:149-55.)
引用
收藏
页码:149 / 155
页数:7
相关论文
共 39 条
[1]   Enhancement of human platelet aggregation and secretion induced by rapamycin [J].
Babinska, A ;
Markell, MS ;
Salifu, MO ;
Akoad, M ;
Ehrlich, YH ;
Kornecki, E .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (12) :3153-3159
[2]   Outcomes and complications associated with off-label and untested use of drug-eluting stents [J].
Beohar, Nirat ;
Davidson, Charles J. ;
Kip, Kevin E. ;
Goodreau, Lynne ;
Aslanidou Vlachos, Helen ;
Meyers, Sheridan N. ;
Benzuly, Keith H. ;
Flaherty, James D. ;
Ricciardi, Mark J. ;
Bennett, Charles L. ;
Williams, David O. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (18) :1992-2000
[3]   Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model [J].
Carter, AJ ;
Aggarwal, M ;
Kopia, GA ;
Tio, F ;
Tsao, PS ;
Kolata, R ;
Yeung, AC ;
Llanos, G ;
Dooley, L ;
Falotico, R .
CARDIOVASCULAR RESEARCH, 2004, 63 (04) :617-624
[4]   Clinical end points in coronary stent trials - A case for standardized definitions [J].
Cutlip, Donald E. ;
Windecker, Stephan ;
Mehran, Roxana ;
Boam, Ashley ;
Cohen, David J. ;
van Es, Gerrit-Anne ;
Steg, P. Gabriel ;
Morel, Marie-angele ;
Mauri, Laura ;
Vranckx, Pascal ;
McFadden, Eugene ;
Lansky, Alexandra ;
Hamon, Martial ;
Krucoff, Mitchell W. ;
Serruys, Patrick W. .
CIRCULATION, 2007, 115 (17) :2344-2351
[5]   PERCUTANEOUS TRANS-LUMINAL CORONARY ANGIOPLASTY IN 1985-1986 AND 1977-1981 - THE NATIONAL-HEART-LUNG-AND-BLOOD-INSTITUTE REGISTRY [J].
DETRE, K ;
HOLUBKOV, R ;
KELSEY, S ;
COWLEY, M ;
KENT, K ;
WILLIAMS, D ;
MYLER, R ;
FAXON, D ;
HOLMES, D ;
BOURASSA, M ;
BLOCK, P ;
GOSSELIN, A ;
BENTIVOGLIO, L ;
LEATHERMAN, L ;
DORROS, G ;
KING, S ;
GALICHIA, J ;
ALBASSAM, M ;
LEON, M ;
ROBERTSON, T ;
PASSAMANI, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (05) :265-270
[6]  
FERES F, 2005, J INVASIVE CARDIOL, V17, P478
[7]   Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions [J].
Grube, E ;
Silber, S ;
Hauptmann, KE ;
Mueller, R ;
Buellesfeld, L ;
Gerckens, U ;
Russell, ME .
CIRCULATION, 2003, 107 (01) :38-42
[8]   Late intravascular ultrasound findings of patients treated with brachytherapy for diffuse in-stent restenosis [J].
Hong, MK ;
Mintz, GS ;
Lee, CW ;
Kim, YH ;
Lee, SW ;
Moon, DH ;
Oh, SJ ;
Song, JM ;
Han, KH ;
Kang, DH ;
Song, JK ;
Kim, JJ ;
Park, SW ;
Park, SJ .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2004, 63 (02) :208-214
[9]   Pathology of drug-eluting stents in humans - Delayed healing and late thrombotic risk [J].
Joner, Michael ;
Finn, Aloke V. ;
Farb, Andrew ;
Mont, Erik K. ;
Kolodgie, Frank D. ;
Ladich, Elena ;
Kutys, Robert ;
Skorija, Kristi ;
Gold, Herman K. ;
Virmani, Renu .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (01) :193-202
[10]   Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents [J].
Kastrati, Adnan ;
Mehilli, Julinda ;
Pache, Juergen ;
Kaiser, Christoph ;
Valgimigli, Marco ;
Kelbaek, Henning ;
Menichelli, Maurizio ;
Sabate, Manel ;
Suttorp, Maarten J. ;
Baumgart, Dietrich ;
Seyfarth, Melchior ;
Pfisterer, Matthias E. ;
Schoemig, Albert .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (10) :1030-1039